Sfunga Therapeutics Overview
- Status
- Private
- Latest Deal Type
- Seed
- Latest Deal Amount
- $30M
- Investors
- 1
Sfunga Therapeutics General Information
Description
Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections. The company's services focus on the improvement of Amphotericin B drug, enabling patients to receive a broad-spectrum of antifungal drug that is completely non-toxic in mammalian cells.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- Boston, MA
- United States
Sfunga Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 22-Jan-2018 | $30M | 0000 | 0000 | Completed | Startup |
Sfunga Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 000 |
Sfunga Therapeutics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Martin Burke Ph.D | Founder |
Sfunga Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Illinois Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |